NC
ESPR

Nexthera Capital’s Esperion Therapeutics ESPR Stock Holding History

Nexthera Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-287,300
Closed -$11.3M – 60
2018
Q2 		$11.3M Buy
+287,300
New +$14.5M 1.74% 17

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Nexthera Capital's ESPR Position: Q3 2018 in Review

Nexthera Capital sold out of Esperion Therapeutics (ESPR) in Q3 2018, closing a stake of 287,300 shares — an estimated $11.3M sold.

Nexthera Capital first reported a position in ESPR in Q2 2018 and held it in 1 quarter. The position peaked at $11.3M in Q2 2018. 155 funds tracked by Wall St. Rank hold ESPR as of Q3 2018.

  • Nexthera Capital reported no remaining Esperion Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Nexthera Capital sold 287,300 Esperion Therapeutics shares in Q3 2018, an estimated $11.3M.
  • Nexthera Capital first reported a position in Esperion Therapeutics in Q2 2018 and held it in 1 quarter.
  • Nexthera Capital's Esperion Therapeutics position peaked at $11.3M in Q2 2018.
  • 155 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2018.

Based on Nexthera Capital's 13F filing for Q3 2018, filed 14 Nov 2018.